Compare Kyndryl Holdings Inc (KD) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kyndryl Holdings Inc vs Summit Therapeutics Inc — how do they compare? Kyndryl Holdings Inc trades at $12.15 (market cap $2.69B), while Summit Therapeutics Inc trades at $14.58 (market cap $10.48B). The key difference: Summit Therapeutics Inc is far larger — about 3.9× Kyndryl Holdings Inc's market cap. Which is the better fit depends on your goals.
| KD | SMMT | |
|---|---|---|
Market Cap | $2.69B | $10.48B |
Sector | Technology | Health |
52-Week High | $39.47 | $29.32 |
52-Week Low | $10.59 | $13.05 |
Enterprise Value | $5.03B | $9.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KD trades at $12.19, up 0.33% on the day, with a neutral technical signal. The company reported revenue of $15.06B in 2025, with net income turning positive to $252M after three years of losses. Recent news includes a partnership with Microsoft for sovereignty solutions and ongoing legal investigations into officers and directors.
The outlook is mixed; improving profitability and a low P/E of 14.38 suggest value, but recent earnings misses and legal scrutiny pose risks. Analyst consensus is a $14.00 price target with a hold rating, indicating cautious optimism amid transformation efforts.
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.
The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
